Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - methylphenidati hydrochloridum - compresse - methylphenidati hydrochloridum 10 mg, tricalcii phosphas, gelatina, lactosum monohydricum 40 mg, magnesii stearas, talcum, tritici amylum 48 mg, pro compresso. - psychotonikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - estradioli valeras, norgestrelum - confetti - i) weisse dragées: estradioli valeras 2 mg, lactosum monohydricum 46.22 mg, maydis amylum, povidonum k 25, talcum, magnesii stearas, saccharum 33.98 mg, povidonum k 90, macrogolum 6000, calcii carbonas, peg montanate, pro compresso obducto. ii) braune dragées: estradioli valeras 2 mg, norgestrelum 0.5 mg, lactosum monohydricum 45.72 mg, maydis amylum, povidonum k 25, magnesii stearas, talcum, saccharum 33.43 mg, povidonum k 90, macrogolum 6000, calcii carbonas, glycerolum (85 per centum), peg montanate, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - disturbi mestruali, perimenopausensyndrom, ormonali ausfallerscheinung - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - isotretinoinum - capsule - isotretinoinum 10 mg, cera flava, sojae oleum hydrogenatum 7.68 mg, sojae oleum partim hydrogenatum 30.72 mg, sojae oleum raffinatum 107.92 mg, kapselhülle: gelatina, glycerolum (85 per centum), sorbitolum 3.05 mg, mannitolum, amylum hydrolysatum hydrogenatum, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, pro capsula. - gravi intrattabile, forme di acne - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - isotretinoinum - capsule - isotretinoinum 20 mg, cera flava, sojae oleum hydrogenatum 15.36 mg, sojae oleum partim hydrogenatum 61.44 mg, sojae oleum raffinatum 215.84 mg, kapselhülle: gelatina, glycerolum (85 per centum), sorbitolum 4.86 mg, mannitolum, amylum hydrolysatum hydrogenatum, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, pro capsula. - gravi intrattabile, forme di acne - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - methylphenidati hydrochloridum - capsule - methylphenidati hydrochloridum 20.00 mg, sacchari sphaerae corresp. saccharum max. 112.77 mg et saccharum mg et maydis amylum, maydis amylum, macrogolum 6000, ammonio methacrylatis copolymerum b, acidi methacrylici copolymerum a, talcum, triethylis citras, kapselhülle: gelatina, e 171, drucktinte: drucktinte: lacca, lacca, propylenglycolum, propylenglycolum q.s., kalii hydroxidum, ammoniae solutio 28 per centum, e 171, kalii hydroxidum, e 172 (rubrum), e 171, e 172 (rubrum), e 172 (flavum), e 172 (flavum), pro capsula. - psychotonikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - methylphenidati hydrochloridum - capsule - methylphenidati hydrochloridum 30 mg, sacchari sphaerae corresp. saccharum max. 169.42 mg et saccharum mg et maydis amylum, maydis amylum, macrogolum 6000, ammonio methacrylatis copolymerum b, acidi methacrylici copolymerum a, talcum, triethylis citras, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: drucktinte: lacca, lacca, propylenglycolum, propylenglycolum, ammoniae solutio 28 per centum, kalii hydroxidum, kalii hydroxidum, e 171, e 172 (rubrum), e 171, e 172 (rubrum), e 172 (flavum), e 172 (flavum), pro capsula, pro capsula. - psychotonikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - methylphenidati hydrochloridum - capsule - methylphenidati hydrochloridum 40 mg, sacchari sphaerae corresp. saccharum mg et saccharum max. 225.89 mg et maydis amylum, maydis amylum, macrogolum 6000, ammonio methacrylatis copolymerum b, acidi methacrylici copolymerum a, talcum, triethylis citras, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), e 172 (nigrum), e 172 (rubrum), drucktinte: pro capsula, lacca, propylenglycolum, ammoniae solutio 28 per centum, kalii hydroxidum, e 171, e 172 (rubrum), e 172 (flavum), pro capsula. - psychotonikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - methylphenidati hydrochloridum - capsule - methylphenidati hydrochloridum 10 mg, sacchari sphaerae corresp. saccharum max. 56.48 mg et saccharum mg et maydis amylum, maydis amylum, macrogolum 6000, ammonio methacrylatis copolymerum b, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, talcum, triethylis citras, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 172 (rubrum), e 172 (nigrum), drucktinte: drucktinte: lacca, lacca, propylenglycolum, propylenglycolum, kalii hydroxidum, ammoniae solutio 28 per centum, e 171, kalii hydroxidum, e 171, e 172 (rubrum), e 172 (rubrum), e 172 (flavum), e 172 (flavum), pro capsula, pro capsula. - psychotonikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - methylphenidati hydrochloridum - capsule - methylphenidati hydrochloridum 60 mg, sacchari sphaerae, macrogolum 6000, saccharum max. 338.85 mg et ammonio methacrylatis copolymerum b, maydis amylum, acidi methacrylici copolymerum a, talcum, triethylis citras, kapselhülle: gelatina, aqua, color.: e 171, e 172, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), drucktinte: lacca, propylenglycolum, ammoniae solutio 28 per centum, kalii hydroxidum, e 171, e 172 (rubrum), e 172 (flavum), pro capsula. - psychotonikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - everolimusum - compresse - everolimusum 5 mg, lactosum 143.75 mg, crospovidonum, hypromellosum, lactosum monohydricum 4.9 mg, magnesio stearas, e 321, pro compresso. - in combinazione con exemestane nelle donne in postmenopausa con carcinoma, hormonrezeptor positivo, her 2 negativo di cancro al seno dopo l'insuccesso di anastrozolo letrozolo o / a economie avanzate, progredienten, bene o moderatamente differenziati tumori neuroendocrini pancreatici origine / avanzate, ben differenziato (g1 o g2), non-funzionale, tumori neuroendocrini gastrointestinali o polmonari di origine con una clinicamente rilevanti progressione tumorale / con carcinoma renale metastatico, dopo fallimento di sunitinib o sorafenib - biotechnologika